Actinogen Medical Limited
ATGGF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $5,490 | $9,932 | $4,888 | $3,640 |
| % Growth | -44.7% | 103.2% | 34.3% | – |
| Cost of Goods Sold | $0 | $0 | $406 | $401 |
| Gross Profit | $5,490 | $9,932 | $4,482 | $3,239 |
| % Margin | 100% | 100% | 91.7% | 89% |
| R&D Expenses | $12,297 | $15,535 | $8,900 | $8,215 |
| G&A Expenses | $2,027 | $1,732 | $1,794 | $1,360 |
| SG&A Expenses | $8,125 | $7,235 | $6,568 | $4,558 |
| Sales & Mktg Exp. | $6,098 | $5,503 | $4,774 | $3,198 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $20,422 | $22,770 | $15,467 | $12,773 |
| Operating Income | -$14,932 | -$12,839 | -$10,580 | -$9,133 |
| % Margin | -272% | -129.3% | -216.4% | -250.9% |
| Other Income/Exp. Net | $200 | -$10,137 | -$173 | -$365 |
| Pre-Tax Income | -$14,732 | -$22,976 | -$10,752 | -$9,497 |
| Tax Expense | $0 | -$9,932 | $0 | $0 |
| Net Income | -$14,732 | -$13,044 | -$10,752 | -$9,497 |
| % Margin | -268.4% | -131.3% | -220% | -260.9% |
| EPS | -0.005 | -0.006 | -0.006 | -0.005 |
| % Growth | 18.3% | -5.3% | -7.5% | – |
| EPS Diluted | -0.005 | -0.006 | -0.006 | -0.005 |
| Weighted Avg Shares Out | 2,979,827 | 2,174,301 | 1,875,607 | 1,787,680 |
| Weighted Avg Shares Out Dil | 2,979,633 | 2,174,301 | 1,875,607 | 1,787,680 |
| Supplemental Information | – | – | – | – |
| Interest Income | $636 | $291 | $367 | $41 |
| Interest Expense | $0 | $24 | $17 | $18 |
| Depreciation & Amortization | $341 | $335 | $406 | $401 |
| EBITDA | -$15,013 | -$12,921 | -$15,218 | -$12,718 |
| % Margin | -273.5% | -130.1% | -311.3% | -349.4% |